Compare Amgen, Inc. (AMGN) vs iShares 3 7 Year Treasury Bond ETF (IEI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs iShares 3 7 Year Treasury Bond ETF — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while iShares 3 7 Year Treasury Bond ETF trades at $116.77. The key difference: Amgen, Inc. pays a 2.77% dividend while iShares 3 7 Year Treasury Bond ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, iShares 3 7 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| AMGN | IEI | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Fixed Income |
52-Week High | $388.16 | $120.72 |
52-Week Low | $271.18 | $116.67 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
IEI (iShares 3-7 Year Treasury Bond ETF) trades at $116.77, down slightly by 0.06% amid broader market volatility. The technical picture remains bearish with moving averages signaling continued pressure, though oscillators show neutral momentum. Recent dividend payments of $0.36-$0.37 highlight the fund's income generation, while bond market uncertainty persists with mixed signals on Federal Reserve policy direction.
The outlook for IEI remains cautious as Treasury yields face upward pressure from inflation concerns and potential Fed rate hikes. While the ETF offers lower volatility than corporate bonds, competition from higher-yielding alternatives like Vanguard's bond ETFs presents headwinds. Key risks include interest rate sensitivity and shifting investor preferences toward higher-yield fixed income options.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About iShares 3 7 Year Treasury Bond ETF
IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →
